Aminoglycosides: Difference between revisions
Jump to navigation
Jump to search
NCLEX nursing pharmacology monographs — batch import |
Add medication infobox (Drugbox) to monographs |
||
| Line 1: | Line 1: | ||
{{Drugbox | |||
| name = Aminoglycosides | |||
| therapeutic = Antibacterial | |||
| pharmacologic = Aminoglycoside | |||
| onset = Rapid IV; dosed by level or extended-interval protocols. | |||
| halflife = Short; gentamicin peak about 5 to 10 mcg/mL and trough below 2 mcg/mL (traditional dosing). | |||
| routes = IV, IM, Inhaled | |||
| highalert = No | |||
| blackbox = <span style="color:#b00020;">'''Yes'''</span> (see Safety) | |||
| antidote = Supportive care. | |||
| pregnancy = Avoid unless essential (fetal ototoxicity). | |||
}} | |||
<div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | <div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | ||
''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ||
Latest revision as of 16:09, 17 June 2026
| Drug monograph · NCLEX study reference | |
| Therapeutic class | Antibacterial |
|---|---|
| Pharmacologic class | Aminoglycoside |
| Onset / peak / duration | Rapid IV; dosed by level or extended-interval protocols. |
| Half-life / level | Short; gentamicin peak about 5 to 10 mcg/mL and trough below 2 mcg/mL (traditional dosing). |
| Routes | IV, IM, Inhaled |
| High-alert (ISMP) | No |
| Black box warning | Yes (see Safety) |
| Antidote / reversal | Supportive care. |
| Pregnancy / lactation | Avoid unless essential (fetal ototoxicity). |
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Aminoglycosides — Antibacterial; Aminoglycoside.
Identification
- Therapeutic class: Antibacterial.
- Pharmacologic class: Aminoglycoside.
Pharmacology
- Mechanism of action: Bind the 30S ribosomal subunit to inhibit protein synthesis (bactericidal); used for serious gram-negative infections.
- Onset / peak / duration: Rapid IV; dosed by level or extended-interval protocols.
- Half-life / therapeutic level: Short; gentamicin peak about 5 to 10 mcg/mL and trough below 2 mcg/mL (traditional dosing).
Clinical use
- Indications: Serious gram-negative and synergy infections; neomycin oral for bowel prep and hepatic encephalopathy; tobramycin inhaled for cystic fibrosis.
- Usual dose, route, frequency: IV or IM by weight and level; inhaled (tobramycin).
- Maximum dose / adjustments: Adjust closely by renal function and serum levels.
Safety
- Contraindications: Hypersensitivity; caution with renal impairment, myasthenia gravis, and prior ototoxicity.
- Black box warning: Nephrotoxicity and ototoxicity (hearing and balance), and potential neuromuscular blockade; monitor renal function and drug levels.
- Interactions: Loop diuretics and other nephrotoxic or ototoxic drugs (vancomycin, amphotericin), neuromuscular blockers.
- Pregnancy / lactation: Avoid unless essential (fetal ototoxicity).
- High-alert: No.
Adverse effects
- Common side effects: Few at therapeutic levels; injection-site reactions.
- Serious effects to report: Hearing loss or tinnitus, vertigo, rising creatinine, decreased urine output.
- Antidote / reversal: Supportive care.
Nursing process
- Assessment before administration: Renal function, baseline hearing, drug levels, weight.
- Interventions during therapy: Draw peak and trough as ordered; assess hearing and balance; ensure hydration.
- Monitor: Peak and trough levels, renal function, hearing and balance, infection resolution.
- Evaluation / expected outcome: Resolution of infection without toxicity.
Patient teaching
- Patient teaching: Report ringing in the ears, hearing changes, or dizziness.
- Notify provider if: Hearing changes, ringing, dizziness, decreased urination.
- Administration tips: Timed level draws; monitor renal and auditory function.